Rearrangements involving the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23 have been discovered in 50% of the cases with IMT.[3,4] As an ALK inhibitor, Crizotinib has been proved effective for ALK-rearranged patients. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.